Related Experiment Videos
Successful autologous peripheral blood stem cell transplantation with rituximab administration for pediatric diffuse
Toshihiko Imamura1, Takao Yoshihara, Akira Morimoto
1Department of Pediatrics, Matushita Memorial Hospital, Moriguchi, Japan. imamura@koto.kpu-m.ac.jp
Abstract:
A 13-year-old boy with chemotherapy-resistant diffuse large B-cell lymphoma (DLBCL) was successfully treated with autologous peripheral blood stem cell transplantation (auto-PBSCT) with administration of rituximab. Previous reports indicate that auto-PBSCT without rituximab for adult chemotherapy-resistant DLBCL is only marginally successful. The addition of rituximab administration might have intensified anti-tumor activity before the transplant procedure and might have enhanced the in vivo purging of the auto-graft, resulting in a successful outcome in this case. Although a few adverse effects are linked to rituximab administration, such as prolonged neutropenia, hypogammaglobulinemia, and increased infectious complications, the regimen of rituximab with SCT appears to be effective against chemotherapy-resistant DLBCL.
